Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Lowy Website

Douglas R. Lowy, M.D.

Selected Publications

1)  Schiller JT, Lowy DR.
Virus infection and human cancer: an overview.
Recent Results Cancer Res. 193: 1-10, 2014.
2)  Handisurya A, Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT.
Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization.
J. Virol. 87: 13214-25, 2013.
3)  Safaeian M, Kemp TJ, Pan DY, Porras C, Cecilia Rodriguez A, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: Results from the Costa Rica Vaccine Trial.
Hum Vaccin Immunother. 9, 2013.
4)  Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA.
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
Cancer Prev Res (Phila). 6: 1242-50, 2013.
5)  Day PM, Thompson CD, Schowalter RM, Lowy DR, Schiller JT.
Identification of a Role for the trans-Golgi Network in Human Papillomavirus 16 Pseudovirus Infection.
J. Virol. 87: 3862-70, 2013.
6)  Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F.
In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells.
BMC Cancer. 13: 198, 2013.
7)  Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang H, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB.
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
J. Virol. 87: 6127-36, 2013.
8)  Lang Kuhs KA, Gonzalez P, Struijk L, Castro F, Hildesheim A, van Doorn LJ, Rodriguez AC, Schiffman M, Quint W, Lowy DR, Porras C, Delvecchio C, Katki HA, Jimenez S, Safaeian M, Schiller J, Solomon D, Wacholder S, Herrero R, Kreimer AR.
Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.
J. Infect. Dis. 208: 1643-52, 2013.
9)  Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR.
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.
PLoS ONE. 8: e68329, 2013.
10)  Wang D, Moothart DR, Lowy DR, Qian X.
The expression of glyceraldehyde-3-phosphate dehydrogenase associated cell cycle (GACC) genes correlates with cancer stage and poor survival in patients with solid tumors.
PLoS ONE. 8: e61262, 2013.
11)  Day PM, Pang YS, Kines RC, Thompson CD, Lowy DR, Schiller JT.
An HPV in vitro neutralization assay that recapitulates the in vivo process of infection provides a sensitive measure of L2 infection-inhibiting antibodies.
Clin Vaccine Immunol. 19: 1075-82, 2012.
12)  Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE.
Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
Vaccine. 30: 6016-9, 2012.
13)  Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, Braverman R, Robles AI, Lowy DR.
Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.
Cancer Res. 72: 4405-16, 2012.
14)  Qian X, Durkin ME, Wang D, Tripathi BK, Olson L, Yang XY, Vass WC, Popescu NC, Lowy DR.
Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.
Cancer Res. 72: 5900-11, 2012.
15)  Çuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM, Lowy DR, Schiller JT.
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
J. Clin. Invest. 122: 4606-20, 2012.
16)  Kemp TJ, Safaeian M, Hildesheim A, Pan Y, Penrose KJ, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA.
Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).
Vaccine. 31: 165-70, 2012.
17)  Handisurya A, Day PM, Thompson CD, Buck CB, Kwak K, Roden RB, Lowy DR, Schiller JT.
Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species.
Virology. 433: 385-94, 2012.
18)  Castro FA, Quint W, Gonzalez P, Katki HA, Herrero R, van Doorn LJ, Schiffman M, Struijk L, Rodriguez AC, DelVecchio C, Lowy DR, Porras C, Jimenez S, Schiller J, Solomon D, Wacholder S, Hildesheim A, Kreimer AR.
Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica.
J. Infect. Dis. 206: 1103-10, 2012.
19)  Lowy DR, Schiller JT.
Reducing HPV-associated cancer globally.
Cancer Prev Res. 5: 18-23, 2012.
20)  Gordon SN, Kines RC, Kutsyna G, Ma ZM, Hryniewicz A, Roberts JN, Fenizia C, Hidajat R, Brocca-Cofano E, Cuburu N, Buck CB, Bernardo ML, Robert-Guroff M, Miller CJ, Graham BS, Lowy DR, Schiller JT, Franchini G.
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.
J. Immunol. 188: 714-23, 2012.
21)  Schiller JT, Lowy DR.
Understanding and learning from the success of prophylactic human papillomavirus vaccines.
Nat. Rev. Microbiol. 10: 681-92, 2012.
22)  Roberts JN, Kines RC, Katki HA, Lowy DR, Schiller JT.
Effect of pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model.
J. Natl. Cancer Inst. 103: 737-43, 2011.
23)  Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn L, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R.
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.
Lancet Oncol. 12: 862-870, 2011.
24)  Coseo SE, Porras C, Dodd LE, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Sherman ME, Jimenez S, Solomon D, Bougelet C, van Doorn LJ, Quint W, Safaeian M.
Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.
Sex Transm Dis. 38: 976-82, 2011.
25)  Li G, Du X, Vass WC, Papageorge AG, Lowy DR, Qian X.
Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Proc. Natl. Acad. Sci. U.S.A. 108: 17129-34, 2011.
26)  Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA.
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
Vaccine. 29: 2011-4, 2011.
27)  Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, Van Doorn LJ, Porras C, Wacholder S, Gonzalez P, Sherman ME, Herrero R.
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease.
J. Infect. Dis. 203: 910-20, 2011.
28)  Buck CB, Lowy DR.
Immune readouts may have prognostic value for the course of merkel cell carcinoma, a virally associated disease.
J. Clin. Oncol. 29: 1506-8, 2011.
29)  Mitsunaga M, Kosaka N, Kines RC, Roberts JN, Lowy DR, Schiller JT, Ishihara Y, Hasegawa A, Choyke PL, Kobayashi H.
In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system.
Cancer Prev Res. 4: 767-73, 2011.
30)  Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR, Porras C, Schussler J, Jimenez S, Sherman ME, Quint W, Schiller JT, Lowy DR, Schiffman M, Hildesheim A.
Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica.
Cancer Discov. 1: 408-419, 2011.
31)  Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S.
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
J. Natl. Cancer Inst. 103: 1444-51, 2011.
32)  Asnaghi L, Vass W, Quadri R, Day P, Qian X, Braverman R, Papageorge A, Lowy D.
E-cadherin negatively regulates abnormal growth in non-small cell lung cancer: role of Rho GTPases.
Oncogene. 29: 2760-71, 2010.
33)  Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT.
In vivo mechanisms of vaccine-induced protection against HPV infection.
Cell Host Microbe. 8: 260-70, 2010.
34)  Lowy DR, Munger K.
Prognostic implications of HPV in oropharyngeal cancer.
N. Engl. J. Med. 363: 82-4, 2010.
35)  de la Luz Sierra M, Sakakibara S, Gasperini P, Salvucci O, Jiang K, McCormick PJ, Segarra M, Stone J, Maric D, Zhu J, Qian X, Lowy DR, Tosato G.
The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1.
Blood. 115: 3970-9, 2010.
36)  Schiller JT, Lowy DR.
Vaccines To Prevent Infections by Oncoviruses.
Annu Rev Microbiol. 64: 23-41, 2010.
37)  Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
J. Natl. Cancer Inst. 101: 782-92, 2009.
38)  García-Piñeres AJ, Hildesheim A, Dodd L, Kemp TJ, Yang J, Fullmer B, Harro C, Lowy DR, Lempicki RA, Pinto LA.
Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients.
J. Immunol. 182: 1706-29, 2009.
39)  Buck CB, Lowy DR.
Getting stronger: the relationship between a newly identified virus and Merkel cell carcinoma.
J. Invest. Dermatol. 129: 9-11, 2009.
40)  Schiller JT, Lowy DR.
Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.
J. Infect. Dis. 200: 166-71, 2009.
41)  Yang XY, Guan M, Vigil D, Der CJ, Lowy DR, Popescu NC.
p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities.
Oncogene. 28: 1401-9, 2009.
42)  Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM.
Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.
J. Virol. 83: 2067-74, 2009.
43)  Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM.
The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding.
Proc. Natl. Acad. Sci. U.S.A. 106: 20458-63, 2009.
44)  Qian X, Li G, Vass W, Papageorge A, Walker R, Asnaghi L, Steinbach P, Tosato G, Hunter K, Lowy D.
The tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis.
Cancer Cell. 16: 246-58, 2009.
45)  Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL.
Arrangement of L2 within the papillomavirus capsid.
J. Virol. 82: 5190-7, 2008.
46)  Porras C, Safaeian M, Gonzalez P, Hildesheim A, Silva S, Schiffman M, Rodriguez AC, Wacholder S, Freer E, Quint K, Bratti C, Espinoza A, Cortes B, Herrero R.
Epidemiology of genital Chlamydia trachomatis infection among young women in Costa Rica.
Sex Transm Dis. 35: 461-8, 2008.
47)  Kemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, Giannini SL, Rodriguez AC, Porras C, Herrero R, Hildesheim A, Pinto LA.
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.
Vaccine. 26: 3608-16, 2008.
48)  Kemp TJ, Hildesheim A, Falk RT, Schiller JT, Lowy DR, Rodriguez AC, Pinto LA.
Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies.
Clin. Vaccine Immunol. 15: 60-4, 2008.
49)  Day PM, Lowy DR, Schiller JT.
Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.
J. Virol. 82: 12565-8, 2008.
50)  Gillison ML, Chaturvedi AK, Lowy DR.
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.
Cancer. 113: 3036-46, 2008.
51)  Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M.
Human papillomavirus infection and the primary and secondary prevention of cervical cancer.
Cancer. 113: 1980-93, 2008.
52)  Lowy D.
Human papillomavirus, cervical cancer prevention, and more.
Vaccine. 26 Suppl 10: iii-iv, 2008.
53)  Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT.
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.
J. Virol. 82: 4638-46, 2008.
54)  Herrero R, Hildesheim A, Rodríguez AC, Wacholder S, Bratti C, Solomon D, González P, Porras C, Jiménez S, Guillen D, Morales J, Alfaro M, Cyr J, Morrisey K, Estrada Y, Cortés B, Morera LA, Freer E, Schussler J, Schiller J, Lowy D, Schiffman M.
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.
Vaccine. 26: 4795-808, 2008.
55)  Lowy DR.
Aaron Lerner: a mentor and friend.
J. Invest. Dermatol. 127: 2092, 2007.
56)  Garcia-Pineres A, Hildesheim A, Dodd L, Kemp TJ, Williams M, Harro C, Lowy DR, Schiller JT, Pinto LA.
Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
Clin. Vaccine Immunol. 14: 984-9, 2007.
57)  Durkin ME, Yuan B, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS, Popescu NC.
DLC-1:a Rho GTPase-activating protein and tumour suppressor.
J. Cell. Mol. Med. 11: 1185-207, 2007.
58)  Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR.
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.
JAMA. 298: 743-53, 2007.
59)  Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT.
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.
Nat. Med. 13: 857-61, 2007.
60)  Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT.
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.
J. Virol. 81: 8784-92, 2007.
61)  Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R, Yamada KM, Popescu NC, Papageorge AG, Lowy DR.
Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.
Proc. Natl. Acad. Sci. U.S.A. 104: 9012-7, 2007.
62)  Frazer IH, Lowy DR, Schiller JT.
Prevention of cancer through immunization: Prospects and challenges for the 21st century.
Eur. J. Immunol. 37 Suppl 1: S148-55, 2007.
63)  Crawford NP, Qian X, Ziogas A, Papageorge AG, Boersma BJ, Walker RC, Lukes L, Rowe WL, Zhang J, Ambs S, Lowy DR, Anton-Culver H, Hunter KW.
Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis.
PLoS Genet. 3: e214, 2007.
64)  Schiller J, Lowy D.
Monsenego J, eds.
Perspectives on HPV Virus-Like Particle Vaccine Efficacy. In: Emerging Issues of HPV Infections: From Science to Practice.
Basel: Karger; 2006. p. 217-226 [Book Chapter]
65)  Howley P, Lowy D.
Knipe K, Howley P, eds.
The Papillomaviruses. In: Fields Virology. Volume 5th Edition.
Baltimore: Lippincott Williams & Wilkens; 2006. p. 3177 pages [Book Chapter]
66)  Lowy D.
Garcea R, DiMaio D, eds.
History of Papillomavirus Research. In: The Papillomaviruses.
New York: Springer; 2006. p. 13-28 [Book Chapter]
67)  Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT.
Carrageenan is a potent inhibitor of papillomavirus infection.
PLoS Pathog. 2: e69, 2006.
68)  Pinto LA, Viscidi R, Harro CD, Kemp TJ, Garcia-Pineres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, Hildesheim A.
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Virology. 353: 451-62, 2006.
69)  Stanley M, Lowy DR, Frazer I.
Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms.
Vaccine. 24 Suppl 3: S106-13, 2006.
70)  Richards RM, Lowy DR, Schiller JT, Day PM.
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.
Proc. Natl. Acad. Sci. U.S.A. 103: 1522-7, 2006.
71)  Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT.
Human alpha-defensins block papillomavirus infection.
Proc. Natl. Acad. Sci. U.S.A. 103: 1516-21, 2006.
72)  Lowy DR, Schiller JT.
Prophylactic human papillomavirus vaccines.
J. Clin. Invest. 116: 1167-73, 2006.
73)  Schiller JT, Lowy DR.
Prospects for cervical cancer prevention by human papillomavirus vaccination.
Cancer Res. 66: 10229-32, 2006.
74)  Schiller J, Lowy D.
Prospects for cervical cancer prevention by human papillomavirus vaccination.
Cancer Res. 66: 10229-32, 2006.
75)  Lowy D, Schiller J.
DeVita V, Hellman V, Rosenberg S, eds.
Preventative Cancer Vaccines. In: Cancer, Principles and Practice of Oncology. Volume 7th Edition.
Philadelphia: Lippincott Williams and Watkins; 2005. p. 2839-2846 [Book Chapter]
76)  Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB.
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
Virology. 337: 365-72, 2005.
77)  Buck CB, Pastrana DV, Lowy DR, Schiller JT.
Generation of HPV pseudovirions using transfection and their use in neutralization assays.
Methods Mol. Med. 119: 445-62, 2005.
78)  Pinto LA, Castle PE, Roden RB, Harro CD, Lowy DR, Schiller JT, Wallace D, Williams M, Kopp W, Frazer IH, Berzofsky JA, Hildesheim A.
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
Vaccine. 23: 3555-64, 2005.
79)  Nardelli-Haefliger D, Lurati F, Wirthner D, Spertini F, Schiller JT, Lowy DR, Ponci F, De Grandi P.
Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.
Vaccine. 23: 3634-41, 2005.
80)  Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT.
Maturation of papillomavirus capsids.
J Virol. 79: 2839-46, 2005.
81)  Lenz P, Lowy DR, Schiller JT.
Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells.
Eur J Immunol. 35: 1548-56, 2005.
82)  Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, Qian X, Hunter KW.
Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1.
Nat Genet. 2005.
83)  Gillison ML, Lowy DR.
A causal role for human papillomavirus in head and neck cancer.
Lancet. 363: 1488-9, 2004.
84)  Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR.
E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.
EMBO J. 23: 1739-84, 2004.
85)  Buck CB, Pastrana DV, Lowy DR, Schiller JT.
Efficient intracellular assembly of papillomaviral vectors.
J Virol. 78: 751-7, 2004.
86)  Day PM, Baker CC, Lowy DR, Schiller JT.
Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.
Proc Natl Acad Sci USA. 101: 14252-14257, 2004.
87)  Schiller JT, Lowy DR.
HPV Vaccines for Cervical Cancer Prevention.
Vaccines, edited by SA Plotkin and WA Orenstein, Elsevier Inc., Philadelphia. 4th Edition: 1259-1265, 2004.
88)  Chackerian B, Briglio L, Albert PS, Lowy DR, Schiller JT.
Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus.
J Virol. 78: 4037-47, 2004.
89)  Schiller JT, Lowy DR.
Preventive Human Papillomavirus Vaccines.
Cervical Cancer: From Etiology to Prevention, edited by T. Rohan and K. Shah, Kluwer Academic Publishers. 325-343, 2004.
90)  Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT.
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
Virology. 321: 205-16, 2004.
91)  Lowy DR, Gillison ML.
A new link between Fanconi anemia and human papillomavirus-associated malignancies.
J Natl Cancer Inst. 95: 1648-50, 2003.
92)  Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A.
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
J Infect Dis. 188: 327-38, 2003.
93)  Lowy DR, Frazer IH.
Chapter 16: Prophylactic human papillomavirus vaccines.
J Natl Cancer Inst Monogr. 111-6, 2003.
94)  Bliskovsky V, Ramsay ES, Scott J, DuBois W, Shi W, Zhang S, Qian X, Lowy DR, Mock BA.
Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.
Proc Natl Acad Sci U S A. 100: 14982-7, 2003.
95)  Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT.
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells.
Clin Immunol. 106: 231-7, 2003.
96)  Zhang S, Qian X, Redman C, Bliskovski V, Ramsay ES, Lowy DR, Mock BA.
p16(INK4a) gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB.
Oncogene. 22: 2285-95, 2003.
97)  Day PM, Lowy DR, Schiller JT.
Papillomaviruses infect cells via a clathrin-dependent pathway.
Virology. 307: 1-11, 2003.
98)  Li S, Braverman R, Li H, Vass WC, Lowy DR, DeClue JE.
Regulation of cell morphology and adhesion by the tuberous sclerosis complex (TSC1/2) gene products in human kidney epithelial cells through increased E-cadherin/beta-catenin activity.
Mol Carcinog. 37: 98-109, 2003.
99)  Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P.
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.
J Natl Cancer Inst. 95: 1128-37, 2003.
100)  Chackerian B, Lenz P, Lowy DR, Schiller JT.
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles.
J Immunol. 169: 6120-6, 2002.
101)  Chackerian B, Lowy DR, Schiller JT.
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies.
J Clin Invest. 108: 415-423, 2001.
102)  Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM, Schiller JT, Bock JE, Sherman ME, Lowy DR, Meijer CL.
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse).
Cancer Epidemiol Biomarkers Prev. 10: 101-6, 2001.
103)  Pastrana DV, Vass WC, Lowy DR, Schiller JT.
HPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.
Virology. 279: 361-369, 2001.
104)  Okun MM, Day PM, Greenstone HL, Booy FP, Lowy DR, Schiller JT, Roden RB.
L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation.
J Virol. 75: 4332-42, 2001.
105)  Schiller JT, Lowy DR.
Papillomavirus-like particle based vaccines: cervical cancer and beyond.
Expert Opin Biol Ther. 1: 571-581, 2001.
106)  Schiller JT, Lowy DR.
Papillomavirus-like particle vaccines.
J. Natl. Cancer Inst. Monogr. 50-4, 2001.
107)  Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, Schiller JT.
Papillomavirus-like particles induce acute activation of dendritic cells.
J Immunol. 166: 5346-5355, 2001.
108)  Lowy DR, Howley PM.
In Fields Virology, edited by Knipe, DM, Howley, PM,, Lippincott Williams and Wilkins, Philadelphia. 4th edition: 2231-2264, 2001.
109)  Roden RB, Day PM, Bronzo BK, Yutzy WH, Yang Y, Lowy DR, Schiller JT.
Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.
J Virol. 75: 10493-10497, 2001.
110)  Bosch FX, Muñoz N, de Sanjosé S, Franco EL, Lowy DR, Schiffman M, Franceschi S, Kjaer SK, Meijer CJ, Frazer IH, Cuzick J.
Re: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer.
J Natl Cancer Inst. 93: 1349-50, 2001.
111)  Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR.
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
J Natl Cancer Inst. 93: 284-292, 2001.
112)  Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT.
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Virology. 270: 254-257, 2000.
113)  Qian X, Esteban L, Vass WC, Upadhyaya C, Papageorge AG, Yienger K, Ward JM, Lowy DR, Santos E.
The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties.
EMBO J. 19: 642-654, 2000.
114)  Anborgh PH, Qian X, Papageorge AG, Vass WC, DeClue JE, Lowy DR.
Ras-specific exchange factor GRF: oligomerization through its Dbl homology domain and calcium-dependent activation of Raf.
Mol Cell Biol. 19: 4611-4622, 1999.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/8/2014.